How to Properly Document the Re-Consent Process with Patients in Clinical Trials

In clinical trials, re-consenting participants is often necessary due to protocol amendments, safety updates, or changes in legal status. However, equally important is the thorough documentation of this re-consent process. Regulatory agencies like the USFDA, EMA, and CDSCO require accurate, verifiable, and version-controlled records of participant consent activities, including any re-consent events. This tutorial provides detailed guidance for documenting re-consent ethically and compliantly.

Why Accurate Re-Consent Documentation Matters:

• Ensures participant understanding and agreement to updated study terms
• Maintains compliance with GMP documentation practices
• Demonstrates adherence to ICH-GCP and local ethics requirements
• Prepares sites for regulatory inspections and sponsor audits
• Prevents legal or ethical concerns from incomplete records

Key Elements of Re-Consent Documentation:

1. Updated Informed Consent Form (ICF)

• Must include new version number and date
• Clearly indicate the changes from previous version (preferably tracked)
• Approved by IRB/EC before use
• Signed and dated by participant and site staff

2. Re-Consent Log

A site-level tracker that includes:

• Subject ID
• Old ICF version and date
• New ICF version and date
• Date re-consent was taken
• Staff initials or signature
• Remarks (e.g., “consented in follow-up visit 3”)

3. Source Documentation

• Include an entry in the subject’s source notes (paper or EHR)
• State the reason for re-consent (e.g., “subject re-consented due to protocol amendment v5.0”)
• Indicate ICF version, date, and staff identity
• Any issues (e.g., patient refused or needed clarification) should be documented

4. Audio-Visual (AV) Consent Recording (India-specific)

As per CDSCO requirements, AV re-recording may be needed for significant changes in ICF:

• Use secure devices with date/time stamps
• Store recordings in access-controlled folders
• Note AV recording ID in source documentation

5. TMF and Investigator Site File (ISF) Filing

• Updated signed ICF copies filed in both participant binder and ISF
• Maintain both old and new versions for audit trail
• Cross-reference in re-consent tracker and protocol amendment log

Step-by-Step Re-Consent Documentation Process:

Step 1: Receive Approved Revised ICF

Obtain Ethics Committee-approved version and distribute to appropriate staff. Use SOP templates for pharma sites to manage version rollout.

Step 2: Re-Consent the Participant

• Explain the changes, reason for re-consent, and answer questions
• Get participant’s signature and date on new ICF
• If LAR is involved, ensure appropriate witness (if required)

Step 3: Record in Source Documentation

Make an entry in the subject’s clinical notes or CRF. For example: “Subject re-consented with ICF version 5.0 dated 12-March-2025 due to protocol changes involving dose escalation. AV recording completed. Signed by Dr. A. Verma.”

Step 4: Update Logs and Systems

• Update ICF tracker, CRF eConsent module (if applicable), and re-consent audit trail log
• File signed ICF in source and ISF within 24 hours
• Notify monitor during next SDV or interim visit

Common Documentation Errors and How to Avoid Them:

Re-Consent Checklist for Documentation:

• Correct and current ICF version used
• Signature/date from participant (and LAR if required)
• Staff signature and printed name
• Entry made in source notes
• AV recording completed and logged (if applicable)
• ICF filed in source and ISF
• Updates made in ICF tracker and CTMS

Regulatory Tips and Best Practices:

• Include consent audit logs as part of monitoring reports
• Use color-coded ICFs or headers to easily identify current versions
• Schedule periodic reviews to archive outdated versions systematically
• Maintain digital and paper trails for redundancy

Digital Consent Tools and Their Role:

Many sites are transitioning to electronic consent (eConsent) systems, which facilitate version tracking, time stamping, and remote audit readiness. Ensure your system meets FDA 21 CFR Part 11 or EMA Annex 11 compliance requirements.

Conclusion:

Documenting the re-consent process is as critical as obtaining the consent itself. Thorough, timely, and compliant documentation ensures ethical standards are upheld and protects both participants and research teams. Whether using paper forms, AV tools, or digital systems, always prioritize clear, traceable records for every re-consent interaction in your clinical trial.